Sweet vaccines are novel carbohydrate based vaccines being developed by the company Malcisbo. The first targets are unmet medical needs such as Campylobacter induced food poisoning and parasitic infections by the blood sucking stomach worm Hemonchus in sheep causing losses in food production. Malcisbo has developed a proprietary target discovery platform which it will use in combination with glycoengineering technologies to provide novel and efficient glycoconjugate vaccines. The discovery platform will generate a constant outflow of novel vaccines for unmet human and veterinary medical needs. Further projects are affordable vaccines to protect people in underdeveloped areas against parasitic worm infections.
View Top Employees from Malcisbo Ltd.Website | http://www.malcisbo.com |
Revenue | $5 million |
Employees | 6 (6 on RocketReach) |
Founded | 2010 |
Address | Wagistrasse 27a, Schlieren, Zurich 8952, CH |
Phone | +41 44 732 22 00 |
Technologies |
JavaScript,
HTML,
PHP
+6 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Health Care, Healthcare, Medical, Drug Manufacturing & Research, Test and Measurement, Biotechnology, Data and Analytics |
Competitors | AiCuris Anti-infective Cures AG, Crown Bioscience, Fluofarma, Redbiotec AG, Resolian |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325414 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Malcisbo Ltd. employee's phone or email?
The Malcisbo Ltd. annual revenue was $5 million in 2024.
6 people are employed at Malcisbo Ltd..
Malcisbo Ltd. is based in Schlieren, Zurich.
The NAICS codes for Malcisbo Ltd. are [325414, 325, 3254, 32541, 32].
The SIC codes for Malcisbo Ltd. are [283, 28].